ZUBSOLV

Peak

buprenorphine hydrochloride and naloxone hydrochloride

NDASUBLINGUALTABLET
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Clinical Trials (1)

NCT02038790Phase 4Completed

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

Started Nov 2013
33 enrolled
Opioid Dependence

Loss of Exclusivity

LOE Date
Sep 18, 2032
79 months away
Patent Expiry
Sep 18, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
8658198
Dec 3, 2027
Product
U-1494
8470361
May 22, 2030
Product
U-1425
11020387
Sep 18, 2032
Product
U-3131
11020388
Sep 18, 2032
Product
U-3131
11433066
Sep 18, 2032
U-3131